DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Canertinib
Canertinib
Vandetanib-Eluting Beads for the Treatment of Liver Tumours
(12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly Et Al
Administration of CI-1033, an Irreversible Pan-Erbb Tyrosine
WO 2013/152252 Al 10 October 2013 (10.10.2013) P O P C T
A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models
Supporting Information
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
Drug-Sensitivity Screening and Genomic Characterization of 45
Vera Lúcia Santos Silva
Customs Tariff - Schedule
WO 2017/180581 Al 19 October 2017 (19.10.2017) P O P C T
Study Protocol and Statistical Analysis Plan
Quantitative Modeling and Analysis of Drug Screening Data for Personalized Cancer Medicine
Oral Adverse Events Associated with Targeted Cancer Therapies
Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations, Biomol
Stembook 2018.Pdf
Nibs: Protein Kinase Inhibitors Kinase Protein Nibs: Formats
Top View
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: a Comprehensive Analysis of the Literature
Canertinib-Induced Leukemia Cell Death Signaling – Effects of a Pan
The Host Cell Virocheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Design of a GAK/EGFR Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma
Identification of Selective Cytotoxic and Synthetic Lethal Drug Responses In
Role of Membrane Transporters in Drug Delivery, Drug Disposition and Drug-Drug Interactions
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Snapshot: Breast Cancer Kornelia Polyak and Otto Metzger Filho Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215 USA
Symposia Saic Satellite Symposium Signal
Computationally Predicting Clinical Drug Combination Efficacy With
Phase I and Pharmacological Study of Pazopanib in Combination with Oral Topotecan in Patients with Advanced Solid Tumours
EGFR Inhibitors Identified As a Potential Treatment for Chordoma in a Focused Compound Screen
Clinical Development of Targeted and Immune Based Anti-Cancer Therapies N
2020.05.19.103945V1.Full.Pdf
Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids